Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/23840
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2030-01-01
Colecciones
- IFF - Artigos de Periódicos [1282]
- INI - Artigos de Periódicos [3460]
- IOC - Artigos de Periódicos [12642]
Metadatos
Mostrar el registro completo del ítem
SECRETORY LEUKOCYTE PROTEASE INHIBITOR EXPRESSION AND HIGH-RISK HPV INFECTION IN ANAL LESIONS OF HIV-POSITIVE PATIENTS
Inibidor Secretado de Peptidases Leucocitárias
Papillomaviridae
Neoplasias
anal intraepithelial neoplasia
human immunodeficiency virus
human papillomavirus
Autor
Afiliación
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ. Brasil.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
Ohio State University. Comprehensive Cancer Center. Columbus, OH, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Departamento de Patologia. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ. Brasil.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
Ohio State University. Comprehensive Cancer Center. Columbus, OH, USA.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira. Departamento de Patologia. Rio de Janeiro, RJ. Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório Interdisciplinar de Pesquisas Médicas. Rio de Janeiro, RJ. Brasil.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
University of Southern California. Norris Comprehensive Cancer Center. Department of Molecular Microbiology and Immunology. Department of Obstetrics and Gynecology. Los Angeles, CA, USA.
Resumen en ingles
Objective: The aim of this study was to evaluate secretory leukocyte
protease inhibitor (SLPI) expression in anal biopsies from HIVpositive
(HIV+) individuals, and compare that to anal intraepithelial
neoplasia (AIN) diagnoses and human papillomavirus (HPV) status.
Design: This is a cross-sectional study of a cohort of 54 HIV+ (31
males and 23 females) from an AIDS clinic in Rio de Janeiro, Brazil.
Methods: The study material consisted of anorectal tissue biopsies
obtained from HIV+ subjects, which were used to construct tissue
microarray paraffin blocks for immunohistochemical analysis of SLPI
expression. Biopsies were evaluated by an expert pathologist and
classified as low-grade AIN1, high-grade AIN2/3, or normal squamous
epithelium. In addition, DNA from the biopsies was extracted
and analyzed for the presence of low- or high-risk HPV DNA.
Results: Histologically, normal squamous epithelium from the
anorectal region showed strong positive SLPI staining in 17/20
(85%) samples. In comparison, 9/17 (53%) dysplastic squamous
epithelial samples from AIN1 patients showed strong SLPI staining,
and only 5/17 (29%) samples from AIN2/3 patients exhibited strong
SPLI staining, which both were significantly fewer than those from
normal tissue (P = 0.005). Furthermore, there was a significantly
higher proportion of samples in which oncogenic high-risk HPV
genotypes were detected in low SLPI-expressing tissues than that in
tissues with high SLPI expression (P = 0.040).
Conclusions: Taken together these results suggest that low SLPI
expression is associated with high-risk HPV infections in the
development of AIN.
Palabras clave en portugues
HIVInibidor Secretado de Peptidases Leucocitárias
Papillomaviridae
Neoplasias
Palabras clave en ingles
secretory leukocyte protease inhibitor,anal intraepithelial neoplasia
human immunodeficiency virus
human papillomavirus
Compartir